From June 11 to 14, 2026, the 20th Asia-Pacific Society of Cardiovascular and Interventional Radiology Congress (APSCVIR 2026) was held at the Suzhou International Expo Center. As one of the most influential academic conferences in interventional radiology and minimally invasive therapy in the Asia-Pacific region, this year's congress brought together interventional specialists, clinical researchers, and young scholars from around the world to exchange insights on frontier topics including interventional oncology, endovascular therapies, and the clinical translation of emerging technologies.

Professor Liao Zhengyin, Distinguished Expert of Chengdu Uni-Asia Cancer Hospital and a renowned senior specialist in interventional therapy in China, was invited to attend the congress and delivered a featured presentation entitled "Cryoablation for Malignant Tumors of the Maxillary Sinus." In his presentation, Professor Liao systematically shared his team's clinical experience and research achievements in minimally invasive treatment for this rare type of malignancy. Through representative clinical cases, he introduced the technical approach, patient selection, efficacy evaluation, and safety management of cryoablation in treating maxillary sinus malignancies, where complex anatomy, limited surgical access, and proximity to critical organs present significant challenges.

Professor Liao stated, "Malignant tumors of the maxillary sinus are located in a highly complex anatomical region, making conventional surgery both highly invasive and high-risk. Cryoablation offers a new treatment option for patients who are not suitable for surgery or who prefer minimally invasive therapy. We are pleased to share our preliminary clinical experience with colleagues across the Asia-Pacific region through the international platform of APSCVIR." A representative of Chengdu Uni-Asia Cancer Hospital noted that the hospital has consistently encouraged its experts to participate in international academic exchanges. Professor Liao's presentation not only showcased the hospital's expertise in minimally invasive oncology but also contributed to international collaboration and the broader adoption of interventional treatment technologies across the region.

As an important minimally invasive treatment modality for cancer, cryoablation has been increasingly adopted in recent years for solid tumors such as lung cancer, liver cancer, and kidney cancer. Professor Liao's team has innovatively extended its application to the treatment of malignant tumors of the maxillary sinus, providing a promising new therapeutic option for patients with this rare disease. Professor Liao delivered both his presentation and the subsequent Q&A session entirely in fluent English, demonstrating his outstanding medical expertise and strong international academic communication skills.

Chengdu Uni-Asia Cancer Hospital remains committed to a patient-centered philosophy while actively promoting the clinical application of advanced interventional technologies. Through flexible talent recruitment and academic collaboration initiatives, the hospital continues to support its specialists in participating in high-level academic exchanges both in China and internationally. Looking ahead, the hospital will continue to leverage the expertise of Professor Liao Zhengyin and other leading specialists to advance the standardization and innovation of minimally invasive cancer therapies.